BYK 321084

Drug Profile

BYK 321084

Alternative Names: BYK321084; PDE4 inhibitor - Nycomed; PDE4 inhibitor – Takeda; PDE4i – Nycomed; TAK-084; Type 4 cyclic nucleotide phosphodiesterase inhibitor – Nycomed

Latest Information Update: 29 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nycomed
  • Developer Takeda Pharmaceuticals International GmbH
  • Class Anti-inflammatories; Antipsoriatics; Phenanthridines; Skin disorder therapies
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Inflammation; Plaque psoriasis

Most Recent Events

  • 29 Apr 2016 No recent reports on development identified - Phase-I for Inflammation in Europe (Topical)
  • 29 Apr 2016 No recent reports on development identified - Phase-I for Plaque psoriasis in Germany (Topical)
  • 29 Apr 2016 Primary efficacy data from a phase I trial in Plaque psoriasis released by Takeda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top